Jundishapur Journal of Microbiology

Published by: Kowsar

In Vitro Antidrug Susceptibility Testing of Candida Species Isolated from Aseptic Body Fluids

Guo-Shi Xiang 1 , 2 , Ling-Bing Zeng 3 , Jie-Yu Zhang 4 , Ying Ying 5 , Xi-Ren Deng 1 , 2 , Xue-Fei Hu 3 , Yan Yan 1 , Ke-Hua Yu 1 , Wei-Wen Zou 1 and Xiao-Tian Huang 1 , 2 , *
Authors Information
1 Department of Medical Microbiology, School of Medicine, Nanchang University, Nanchang, China
2 Key Laboratory of Tumor Pathogenesis and Molecular Pathology, School of Medicine, Nanchang University, Nanchang, China
3 Department of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, China
4 Department of Pathophysiology, School of Medicine, Nanchang University, Nanchang, China
5 Department of Pathophysiology, Fuzhou Medical School, Nanchang University, Fuzhou , China
Article information
  • Jundishapur Journal of Microbiology: August 2018, 11 (8); e55547
  • Published Online: July 25, 2018
  • Article Type: Research Article
  • Received: June 18, 2017
  • Revised: May 14, 2018
  • Accepted: May 27, 2018
  • DOI: 10.5812/jjm.55547

To Cite: Xiang G, Zeng L, Zhang J, Ying Y, Deng X, et al. In Vitro Antidrug Susceptibility Testing of Candida Species Isolated from Aseptic Body Fluids, Jundishapur J Microbiol. 2018 ; 11(8):e55547. doi: 10.5812/jjm.55547.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37(9):1172-7. doi: 10.1086/378745. [PubMed: 14557960].
  • 2. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care. 2010;16(5):445-52. doi: 10.1097/MCC.0b013e32833e84d2. [PubMed: 20711075].
  • 3. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol. 2010;36(1):1-53. doi: 10.3109/10408410903241444. [PubMed: 20088682].
  • 4. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010;48(4):1366-77. doi: 10.1128/JCM.02117-09. [PubMed: 20164282]. [PubMed Central: PMC2849609].
  • 5. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-9. doi: 10.1001/jama.2009.1754. [PubMed: 19952319].
  • 6. Li S, An YZ. [Retrospective analysis of invasive fungal infection in surgical intensive care unit]. Zhonghua Yi Xue Za Zhi. 2010;90(6):382-5. [PubMed: 20367934].
  • 7. Kett DH, Azoulay E, Echeverria PM, Vincent JL; Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39(4):665-70. doi: 10.1097/CCM.0b013e318206c1ca. [PubMed: 21169817].
  • 8. Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol. 2011;3:175-91. doi: 10.2147/CLEP.S12502. [PubMed: 21750627]. [PubMed Central: PMC3130903].
  • 9. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis. 2010;14(11):e954-66. doi: 10.1016/j.ijid.2010.04.006. [PubMed: 20797887].
  • 10. Echeverria PM, Kett DH, Azoulay E. Candida prophylaxis and therapy in the ICU. Semin Respir Crit Care Med. 2011;32(2):159-73. doi: 10.1055/s-0031-1275528. [PubMed: 21506052].
  • 11. Luo G, Mitchell TG. Rapid identification of pathogenic fungi directly from cultures by using multiplex PCR. J Clin Microbiol. 2002;40(8):2860-5. [PubMed: 12149343]. [PubMed Central: PMC120665].
  • 12. Chang HC, Leaw SN, Huang AH, Wu TL, Chang TC. Rapid identification of yeasts in positive blood cultures by a multiplex PCR method. J Clin Microbiol. 2001;39(10):3466-71. doi: 10.1128/JCM.39.10.3466-3471.2001. [PubMed: 11574557]. [PubMed Central: PMC88373].
  • 13. Chen YC, Eisner JD, Kattar MM, Rassoulian-Barrett SL, Lafe K, Bui U, et al. Polymorphic internal transcribed spacer region 1 DNA sequences identify medically important yeasts. J Clin Microbiol. 2001;39(11):4042-51. doi: 10.1128/JCM.39.11.4042-4051.2001. [PubMed: 11682528]. [PubMed Central: PMC88485].
  • 14. Rex JH. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard. 2 ed. Clinical and Laboratory Standards Institute; 2008.
  • 15. Alexander BD. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4 ed. Clinical and Laboratory Standards Institute; 2017.
  • 16. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012;50(9):2846-56. doi: 10.1128/JCM.00937-12. [PubMed: 22740712]. [PubMed Central: PMC3421803].
  • 17. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005;49(2):668-79. doi: 10.1128/AAC.49.2.668-679.2005. [PubMed: 15673750]. [PubMed Central: PMC547307].
  • 18. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2002;46(6):1704-13. [PubMed: 12019079]. [PubMed Central: PMC127245].
  • 19. Liu W, Tan J, Sun J, Xu Z, Li M, Yang Q, et al. Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study. J Antimicrob Chemother. 2014;69(1):162-7. doi: 10.1093/jac/dkt330. [PubMed: 24004860].
  • 20. Hazen KC, Baron EJ, Colombo AL, Girmenia C, Sanchez-Sousa A, del Palacio A, et al. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol. 2003;41(12):5623-32. [PubMed: 14662952]. [PubMed Central: PMC309015].
  • 21. Schmalreck AF, Willinger B, Haase G, Blum G, Lass-Florl C, Fegeler W, et al. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study. Mycoses. 2012;55(3):e124-37. doi: 10.1111/j.1439-0507.2011.02165.x. [PubMed: 22233267].
  • 22. Cuenca-Estrella M, Rodero L, Garcia-Effron G, Rodriguez-Tudela JL. Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J Antimicrob Chemother. 2002;49(6):981-7. [PubMed: 12039890].
  • 23. Yang YL, Chen HT, Lin CC, Chu WL, Lo HJ; Tsary Hospitals. Species distribution and drug susceptibilities of Candida isolates in TSARY 2010. Diagn Microbiol Infect Dis. 2013;76(2):182-6. doi: 10.1016/j.diagmicrobio.2013.03.003. [PubMed: 23574935].
  • 24. Zhang XB, Yu SJ, Yu JX, Gong YL, Feng W, Sun FJ. Retrospective analysis of epidemiology and prognostic factors for candidemia at a hospital in China, 2000-2009. Jpn J Infect Dis. 2012;65(6):510-5. [PubMed: 23183203].
  • 25. Li F, Wu L, Cao B, Zhang Y, Li X, Liu Y. Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011. BMC Infect Dis. 2013;13:353. doi: 10.1186/1471-2334-13-353. [PubMed: 23899244]. [PubMed Central: PMC3733982].
  • 26. Mulu A, Kassu A, Anagaw B, Moges B, Gelaw A, Alemayehu M, et al. Frequent detection of 'azole' resistant Candida species among late presenting AIDS patients in northwest Ethiopia. BMC Infect Dis. 2013;13:82. doi: 10.1186/1471-2334-13-82. [PubMed: 23398783]. [PubMed Central: PMC3577436].
  • 27. Badiee P, Alborzi A. Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study. Iran J Microbiol. 2011;3(4):183-8. [PubMed: 22530086]. [PubMed Central: PMC3330181].
  • 28. Jayachandran AL, Katragadda R, Thyagarajan R, Vajravelu L, Manikesi S, Kaliappan S, et al. Oral Candidiasis among Cancer Patients Attending a Tertiary Care Hospital in Chennai, South India: An Evaluation of Clinicomycological Association and Antifungal Susceptibility Pattern. Can J Infect Dis Med Microbiol. 2016;2016:8758461. doi: 10.1155/2016/8758461. [PubMed: 27403171]. [PubMed Central: PMC4923570].
  • 29. Lyon GM, Karatela S, Sunay S, Adiri Y, Candida Surveillance Study I. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. 2010;48(4):1270-5. doi: 10.1128/JCM.02363-09. [PubMed: 20129963]. [PubMed Central: PMC2849617].
  • 30. Kontoyiannis DP. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis. Clin Infect Dis. 2002;34(9):1281-3. author reply 1283. doi: 10.1086/339946. [PubMed: 11941561].
  • 31. Pfaller MA, Castanheira M, Messer SA, Jones RN. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012. Mycoses. 2015;58(4):209-14. doi: 10.1111/myc.12299. [PubMed: 25727853].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments